Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Tomaschitz, A; Fahrleitner-Pammer, A; Pieske, B; Verheyen, N; Amrein, K; Ritz, E; Kienreich, K; Horina, JH; Schmidt, A; Kraigher-Krainer, E; Colantonio, C; Meinitzer, A; Pilz, S.
Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial.
BMC Endocr Disord. 2012; 12(12):19-19
Doi: 10.1186/1472-6823-12-19
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Tomaschitz Andreas
- Co-Autor*innen der Med Uni Graz
- Amrein Karin
- Colantonio Caterina
- Fahrleitner-Pammer Astrid
- Horina Joerg
- Kienreich Katharina
- Kraigher-Krainer Elisabeth
- Meinitzer Andreas
- Pieske Burkert Mathias
- Pilz Stefan
- Schmidt Albrecht
- Verheyen Nicolas Dominik
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Increasing evidence suggests the bidirectional interplay between parathyroid hormone and aldosterone as an important mechanism behind the increased risk of cardiovascular damage and bone disease observed in primary hyperparathyroidism. Our primary object is to assess the efficacy of the mineralocorticoid receptor-blocker eplerenone to reduce parathyroid hormone secretion in patients with parathyroid hormone excess. Overall, 110 adult male and female patients with primary hyperparathyroidism will be randomly assigned to eplerenone (25 mg once daily for 4 weeks and 4 weeks with 50 mg once daily after dose titration] or placebo, over eight weeks. Each participant will undergo detailed clinical assessment, including anthropometric evaluation, 24-h ambulatory arterial blood pressure monitoring, echocardiography, kidney function and detailed laboratory determination of biomarkers of bone metabolism and cardiovascular disease.The study comprises the following exploratory endpoints: mean change from baseline to week eight in (1) parathyroid hormone(1-84) as the primary endpoint and (2) 24-h systolic and diastolic ambulatory blood pressure levels, NT-pro-BNP, biomarkers of bone metabolism, 24-h urinary protein/albumin excretion and echocardiographic parameters reflecting systolic and diastolic function as well as cardiac dimensions, as secondary endpoints. In view of the reciprocal interaction between aldosterone and parathyroid hormone and the potentially ensuing target organ damage, the EPATH trial is designed to determine whether eplerenone, compared to placebo, will effectively impact on parathyroid hormone secretion and improve cardiovascular, renal and bone health in patients with primary hyperparathyroidism. ISRCTN33941607.
- Find related publications in this database (Keywords)
- Aldosterone
- Mineralocorticoid receptor blocker
- Hyperparathyroidism